Seed Funding Round: £1M

NanoLipo Cancer Solutions is seeking £1,000,000 in seed funding in exchange for equity shares to complete the final preclinical phase of development for our microfluidic liposomal Doxorubicin platform.

The funds will be allocated to core technical execution, including specialised materials and consumables, laboratory rental and equipment access, and the continued development of our microfluidic manufacturing capabilities.

Capital will also support staffing costs for a lean operating team, comprising four directors overseeing strategy, regulatory planning, and business development, alongside two dedicated R&D scientists responsible for laboratory and technical operations.

This funding will enable the critical steps required to transition from validated laboratory research to clinical readiness, including:

• GLP toxicology studies to establish safety and dosage parameters.

• CMC (Chemistry, Manufacturing, and Controls) dossier development to support MHRA and international regulatory submissions.

• Intellectual property expansion and protection, covering formulation, process, and microfluidic manufacturing methods.

• Quality and regulatory framework development aligned with MHRA, EMA, and future GMP requirements.

Why Investing

NanoLipo represents a differentiated opportunity in oncology drug delivery at a stage where technical risk has been substantially reduced and future value creation is clearly defined.

The company combines early in-vitro and in-vivo validation with a realistic MHRA-aligned regulatory strategy, a defensible draft-filed IP portfolio, and a scalable microfluidic manufacturing platform adaptable across multiple oncology drugs.

With strong cost-efficiency compared to existing liposomal methods and multiple near-term value inflection points, particularly preclinical completion and Phase I readiness.

NanoLipo is positioned to deliver meaningful scientific impact alongside attractive commercial returns.

The Strategic Roadmap: Value Inflection Points

The journey from a laboratory concept to a market-ready pharmaceutical product is marked by specific stages of "de-risking." Each stage represents a significant jump in company valuation as technical and regulatory uncertainties are removed.

• Stage 1 - Preclinical Validation (0–18 Months)

Our initial focus is the completion of in-vitro and in-vivo efficacy data, alongside GLP toxicology. By securing a robust CMC dossier and filing international patents, we transform NanoLipo into a defensible, IP-backed oncology asset.

• Stage 2 - Clinical Readiness (18–36 Months)

Upon achieving regulatory alignment with the MHRA or EMA and establishing GMP manufacturing readiness, the company enters the "Clinical Validation" phase. Moving toward Phase I initiation significantly reduces the risk for potential acquirers.

• Stage 3 - Platform Expansion or Liquidity (36+ Months)

Once the platform is validated, we move to high-value licensing, a strategic acquisition, or the expansion of the pipeline into multiple oncology indications.

Valuation Framework

NanoLipo’s valuation is grounded in conservative, benchmark-driven data from the nanomedicine and drug-delivery sectors. We identify two primary windows for significant valuation growth.

The first window occurs upon the completion of Preclinical Milestones. Once GLP toxicology and in-vivo efficacy are validated, NanoLipo becomes a de-risked asset with an indicative valuation range of £7M – £15M, offering seed investors clear multiple expansion based on data and IP alone.

The second window opens during Phase I Readiness. As we move toward human trials, the valuation shifts toward clinical-stage benchmarks, typically ranging from £25M to £50M+. This increase is driven by major regulatory risk reduction and "platform optionality", the ability to apply our microfluidic technology to a wide array of other oncology drugs beyond Doxorubicin.

Diversified Return Pathways and Exit Strategies

NanoLipo Cancer Solutions is engineered with a disciplined approach to long-term value creation. While our primary objective is the clinical and commercial validation of a next-generation microfluidic liposomal platform, we recognize that a sophisticated exit strategy is a prerequisite for professional investment.

We do not view an exit as a singular, forced event, but rather as a series of contingency pathways designed to protect capital and maximize returns at defined technical milestones.

Our strategy centers on "de-risking" the asset. By focusing on a product-first and platform-driven model, starting with our proprietary Doxorubicin formulation, we build tangible value that is attractive to the pharmaceutical industry long before reaching the most expensive stages of clinical development.

To ensure investor liquidity, we have structured four distinct pathways to realize returns. This multi-pronged approach reduces reliance on a single market outcome and provides "downside protection" for our partners.

• Platform Expansion

NanoLipo aims to evolve into a multi-asset nanomedicine platform, increasing valuation through pipeline depth and leading to higher acquisition values or later-stage investment.

• Licensing & Royalty Model

We can license our specific formulation or the underlying manufacturing platform. This generates immediate upfront fees and milestone payments followed by long-term royalty streams.

• Strategic Acquisition

Large or mid-sized pharmaceutical companies often acquire platform technologies like NanoLipo to upgrade legacy products or secure superior manufacturing capabilities, offering a full or partial exit at a premium.

• Asset Sale (Capital Preservation)

In the event of shifting market conditions, NanoLipo retains value through its transferable assets. Our patents, formulation rights, and manufacturing know-how can be sold independently to ensure capital recovery.

Why this model is realistic

NanoLipo’s strategy mirrors the outcomes of successful liposomal oncology acquisitions and drug-delivery licensing deals. Our competitive advantage lies in our microfluidic precision, which allows for scalable, cost-efficient manufacturing and a reduced cardiotoxicity profile. By aligning our scientific development with a clear regulatory and IP strategy from the outset, we maintain the flexibility to pursue the most value-accretive pathway as the market evolves.

The investment strategy and use of proceeds are supported by a comprehensive and detailed business plan that clearly defines each technical, commercial, and regulatory pathway. The plan also includes a full financial forecast with a detailed breakdown of anticipated expenses. This document is available to prospective investors upon request and subject to a non-disclosure agreement.